Iron supplementation: Difference between revisions

(Text replacement - "Category:Drugs" to "Category:Pharmacology")
No edit summary
 
(2 intermediate revisions by 2 users not shown)
Line 1: Line 1:
==Background==
==Background==
There are multiple types of oral and intravenous therapyIV therapy is usually reserved for patients undergoing epoetin therapy or severely anemic [[Jehovah's Witness patients]] and should be cautiously administered due to the risk of anaphylaxis with some preparations.<ref name="Macdougall">Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl. 1999;69:S61-S66.</ref>
*Multiple types of oral and intravenous therapy available
*IV therapy is usually reserved for patients undergoing epoetin therapy or severely anemic [[Jehovah's Witness patients]]
**Should be cautiously administered due to the risk of [[anaphylaxis]] with some preparations.<ref name="Macdougall">Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl. 1999;69:S61-S66.</ref>


==Oral Preparations==
==Oral Preparations==
Recommended oral daily dose for the treatment of iron deficiency in adults is in the range of 150 to 200 mg/day of elemental iron
Recommended oral daily dose for the treatment of iron deficiency in adults is in the range of 150 to 200mg/day of elemental iron
*Ferrous Sulfate
*Ferrous Sulfate
*Ferrous fumarate
*Ferrous fumarate
Line 19: Line 21:
===IV iron Regimens===
===IV iron Regimens===
====Low dose====
====Low dose====
*20–60 mg every dialysis session<ref name="Macdougall"></ref>
*20–60mg every dialysis session<ref name="Macdougall"></ref>
*Hemodialysis patients only
*Hemodialysis patients only
*Any of iron preparations suitable
*Any of iron preparations suitable
*May be given as IV push
*May be given as IV push
====Medium dose====
====Medium dose====
*100–400 mg as IV infusion
*100–400mg as IV infusion
*All iron preparations (maximum dose of iron sodium gluconate is 62.5–125mg)
*All iron preparations (maximum dose of iron sodium gluconate is 62.5–125mg)
====High dose====
====High dose====
*500–1000 mg
*500–1000mg
*Must be given as IV infusion
*Must be given as IV infusion
*Only iron dextran suitable
*Only iron dextran suitable
Line 44: Line 46:


[[Category:Pharmacology]]
[[Category:Pharmacology]]
[[Category:FEN]]

Latest revision as of 16:17, 29 September 2019

Background

  • Multiple types of oral and intravenous therapy available
  • IV therapy is usually reserved for patients undergoing epoetin therapy or severely anemic Jehovah's Witness patients
    • Should be cautiously administered due to the risk of anaphylaxis with some preparations.[1]

Oral Preparations

Recommended oral daily dose for the treatment of iron deficiency in adults is in the range of 150 to 200mg/day of elemental iron

  • Ferrous Sulfate
  • Ferrous fumarate
  • Ferrous gluconate
  • Ferrous succinate

Elemental Iron Percentages

Elemental Iron Percentages

Iron Preparation % of Elemental Iron
Ferrous Fumarate 33%
Ferrous Sulfate 20%
Ferrous Gluconate 12%
Ferric pyrophosphate 30%
Ferroglycine sulfate 16%
Ferrous carbonate (anhydrous) 38%

Intravenous Preparations

Occasionally used by nephrologists and patients receiving epoitin. IV iron can increase hemoglobin concentrations by 1-2 g/dL

  • Iron dextran
  • Iron dextrin
  • Iron sodium gluconate
  • Iron hyroxysaccharate

IV iron Regimens

Low dose

  • 20–60mg every dialysis session[1]
  • Hemodialysis patients only
  • Any of iron preparations suitable
  • May be given as IV push

Medium dose

  • 100–400mg as IV infusion
  • All iron preparations (maximum dose of iron sodium gluconate is 62.5–125mg)

High dose

  • 500–1000mg
  • Must be given as IV infusion
  • Only iron dextran suitable
  • Only for patients with large iron deficit and resistance to all other treatment regemins

Intramuscular preparations

Rarely if ever used

  • Iron sorbitol citrate is only possible formulation

See Also

References

  1. 1.0 1.1 Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl. 1999;69:S61-S66.